The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 28, 2014
Filed:
Apr. 08, 2005
George M. Shaw, Birmingham, AL (US);
James E. Robinson, New Orleans, LA (US);
Frederic Bibollet-ruche, Birmingham, AL (US);
Julie M. Decker, Alabaster, AL (US);
Beatrice H. Hahn, Birmingham, AL (US);
Peter D. Kwong, Bethesda, MD (US);
George M. Shaw, Birmingham, AL (US);
James E. Robinson, New Orleans, LA (US);
Frederic Bibollet-Ruche, Birmingham, AL (US);
Julie M. Decker, Alabaster, AL (US);
Beatrice H. Hahn, Birmingham, AL (US);
Peter D. Kwong, Bethesda, MD (US);
UAB Research Foundation, Birmingham, AL (US);
The Administrators of Tulane Educational Fund, New Orleans, LA (US);
The United States of America, as represented by the Secretary, Department of Health and Human Services, Washington, DC (US);
Abstract
Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and/or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.